New drug combo aims to boost stroke recovery

NCT ID NCT07026318

Recruiting now Disease control Sponsor: Beijing Anzhen Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether adding the drug tirofiban after a standard clot-removal procedure helps people recover better from a severe stroke caused by a blocked artery. About 716 adults will receive either tirofiban or a placebo right after the procedure. The main goal is to see if more people achieve functional independence (able to care for themselves) three months later, while also checking for any increased risk of brain bleeding.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tirofiban
What this could lead to: If successful, adding tirofiban after clot removal could become a standard treatment to improve functional recovery after a stroke.
What could go wrong: This is a mid-stage trial, so results are not yet proven. The main risk is increased bleeding in the brain, which the study is carefully monitoring.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke large artery stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE ISCHEMIC STROKE

Contacts and locations

Locations

Beijing Anzhen Hospital Affiliated to Capital Medical University
RECRUITING

Beijing, Beijing Municipality, 101118, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.